Tumor Cell Or Cancer Cell Patents (Class 435/7.23)
-
Patent number: 8940493Abstract: Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.Type: GrantFiled: May 29, 2007Date of Patent: January 27, 2015Assignees: Veridex LLC, Pfizer Inc.Inventors: Antonio Gualberto, Maria Luisa Paccagnella, Carrie L. Melvin, Madeline I. Repollet, David Chianese, Mark Carle Connelly, Leonardus Wendelinus Mathias Marie Terstappen
-
Patent number: 8940298Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.Type: GrantFiled: September 4, 2008Date of Patent: January 27, 2015Assignee: The Regents of the University of CaliforniaInventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
-
Patent number: 8940497Abstract: A multidimensional profiling strategy that combines activity-based proteomics and metabolomics was used to determine that an active protein, which is a previously uncharacterized enzyme highly elevated in aggressive cancer cells, serves as a central node in an ether lipid signaling network that bridges platelet-activating factor and the lysophospholipids. Biochemical studies confirmed that the active protein regulates this pathway by hydrolyzing the metabolic intermediate 2-acetyl monoalkylglycerol. Inactivation of the active protein disrupted ether lipid metabolism in cancer cells and impaired cell migration and tumor growth in vivo.Type: GrantFiled: August 14, 2012Date of Patent: January 27, 2015Assignee: The Scripps Research InstituteInventors: Benjamin F. Cravatt, Kyle P. Chiang, Sherry Niessen, Alan Saghatelian
-
Publication number: 20150024409Abstract: Disclosed herein are methods and systems for determining whether a cell is resistant to one or more drugs. Also, disclosed herein are methods and systems for monitoring the treatment of a cancer patient to determine whether the cancerous cells being treated are resistant to the treatment. Further, disclosed herein are methods and systems for predicting the responsiveness of a cell to a drug.Type: ApplicationFiled: February 21, 2013Publication date: January 22, 2015Inventor: Nahid Razi
-
Patent number: 8936914Abstract: The present invention provides methods of aiding in a renal cell carcinoma prognosis that include quantifying expressed carbonic anhydrase in samples derived from renal cell carcinoma patients. The methods also identify patients that are likely to respond positively to selected courses of treatment. The invention further provides related computer program products.Type: GrantFiled: April 15, 2003Date of Patent: January 20, 2015Assignee: The Regents of the University of CaliforniaInventors: Matthew H. T. Bui, David Seligson, Arie S. Belldegrun
-
Publication number: 20150017230Abstract: An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer cells expressing EpCAM said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (NPC), colorectal cancer cells, and ovarian cancer cells; and (c) having no binding affinity to human umbilical vein endothelial cell (HUVEC) and normal nasal mucosal epithelia (NNM). Also disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion molecule (EpCAM). Methods of using the same are also disclosed.Type: ApplicationFiled: March 1, 2013Publication date: January 15, 2015Applicant: ACADEMIA SINICAInventors: Han-Chung Wu, Mei-Ying Liao, Cheng-Wei Lin
-
Publication number: 20150017119Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.Type: ApplicationFiled: May 16, 2014Publication date: January 15, 2015Applicant: Nodality, Inc.Inventors: Wendy J. FANTL, David B. ROSEN, Alessandra CESANO, Santosh K. PUTTA, Garry NOLAN, Aileen COHEN, Erik EVENSEN
-
Publication number: 20150017663Abstract: Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells.Type: ApplicationFiled: February 22, 2013Publication date: January 15, 2015Applicant: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohit B. Bhatia, Qian Ye
-
Publication number: 20150017637Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to gene fusions as diagnostic markers and clinical targets for cancer.Type: ApplicationFiled: July 11, 2014Publication date: January 15, 2015Inventors: Arul Chinnaiyan, Yi-Mi Wu, Dan Robinson
-
Publication number: 20150017662Abstract: The present invention is a method for detecting or quantifying a target cell or a target protein using an aptamer chip, and particularly, in order to detect a target cell, a method for detecting and/or quantifying a target cell by reacting a cell staining solution (e.g. 4?,6-diamidino-2-phenylindole (DAPI)) with an aptamer chip which the target cell is bound, in order to detect a target protein, a method for detecting and/or quantifying a target protein by reacting Coomassie Brilliant Blue solution with an aptamer chip which the target protein is bound, and a method for reusing the aptamer chip, wherein the aptamer chip comprises a board to which the aptamer specifically combining with the target cell or the target protein is bonded by a disulfide bond.Type: ApplicationFiled: January 14, 2013Publication date: January 15, 2015Applicant: University-Industry Cooperation Group fo Kyung Hee UniversityInventors: Sang Soo Hah, Gwan Ho Lee, Ji Su Kim
-
Publication number: 20150017661Abstract: Methods are provided for detecting 5T4-positive circulating tumor cells in a mammalian subject. Methods of diagnosing 5T4-positive cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of 5T4-positive metastatic cancer or early stage 5T4-positive cancer.Type: ApplicationFiled: January 22, 2013Publication date: January 15, 2015Inventors: Steven Pirie-Shepherd, Hans-Peter Gerber, Dena Marrinucci, Eric Tucker
-
Publication number: 20150018239Abstract: The present invention relates to a method for differentiating between i) a severe form of cancer and ii) a mild form of cancer, comprising a) determining the amounts of gene product of at least the genes coding for ribosomal protein S6 (RPS6), nucleoside diphosphate kinase (NME/NDKA), and caveolin-1, in a sample from a subject, b) comparing the amounts obtained in step a) to reference amounts, and c) differentiating between a severe form of cancer and a mild form of cancer, wherein an increased amount of products of the genes coding for RPS6 and NME/NDKA and a decreased amount of product of the gene coding for caveolin-1 are indicative of a severe form of cancer. The invention further relates to the use of antibodies specifically recognizing a polypeptide selected from the list consisting of RPS6, NME/NDKA, and caveolin-1, for differentiating between a severe form of cancer and a mild form of cancer.Type: ApplicationFiled: February 8, 2013Publication date: January 15, 2015Applicant: Deutsches KrebsforschungszentrumInventors: Johanna Sonntag, Christian Bender, Ulrike Korf, Stefan Wiemann
-
Publication number: 20150017660Abstract: The present invention is to provide a method of exosome analysis that can analyze exosome in a sample in a simple manner. The method of exosome analysis of the present invention is a method of analyzing exosome in a sample, including: an addition step of adding a first antibody that specifically binds to a first antigen contained in the exosome and a second antibody that specifically binds to a second antigen contained in the exosome to the sample; a reaction step of causing the first antigen to be reacted with the first antibody and the second antigen to be reacted with the second antibody; and a detection step of detecting a reaction between the first antigen and the first antibody and a reaction between the second antigen and the second antibody.Type: ApplicationFiled: October 25, 2012Publication date: January 15, 2015Inventor: Takahiro OCHIYA
-
Publication number: 20150017091Abstract: The establishment and growth of metastatic tumors can be detected and inhibited by the methods and compositions described herein. As illustrated herein, agents that inhibit the expression or activity of versican, for example, in bone marrow cells effectively halt the growth and establishment of metastatic tumors at distal sites from a primary tumor site. In general, the primary tumor is unaffected by versican inhibitors but metastasis is substantially eliminated.Type: ApplicationFiled: August 16, 2012Publication date: January 15, 2015Inventors: Vivek Mittal, Ding Cheng Gao
-
Patent number: 8932824Abstract: The present invention provides a method for detecting or screening for the presence of cancer in a subject. The method comprises obtaining, providing or collecting a tissue or fluid sample (such as a urine sample) from said subject, and then determining the presence or absence of delta-catenin in said sample, or increased levels of delta-catenin in said sample as compared to a normal or control subject. The presence of delta-catenin in said sample, or increased levels of delta-catenin in said sample, indicating said subject is afflicted with or at least at risk of developing cancer.Type: GrantFiled: October 3, 2011Date of Patent: January 13, 2015Assignee: East Carolina UniversityInventors: Qun Lu, Yan-hua Chen
-
Patent number: 8932590Abstract: An adsorbent for immunosuppressive substance, which can adsorb an excessive immunosuppressive substance directly from a body fluid, can carry out extracorporeal perfusion safely and can be utilized in treatment of cancer. The excessive immunosuppressive substance may be involved in growth of cancer cells. The adsorbent for immunosuppressive substance includes a water-insoluble carrier and a hydrophilic amino group immobilized to the water-insoluble carrier. An extracorporeal perfusion column contains the adsorbent of the invention. A method for treating cancer carries out extracorporeal perfusion using the extracorporeal perfusion column. A method of adsorbing the transforming growth factor ? which is combined with another protein, includes adsorbing the transforming growth factor ? and protein on an adsorbent containing a water-insoluble carrier to which quaternary ammonium groups each having 3 to 18 carbon atoms per one nitrogen atom are attached, and having a specific surface area of 0.Type: GrantFiled: June 15, 2011Date of Patent: January 13, 2015Assignee: TORAY Industries, Inc.Inventors: Kazuo Teramoto, Toshio Yoshioka, Masaaki Shimagaki, Takeo Matsunase, Koji Watanabe, Yuji Ueda, Yoshiki Yamamoto
-
Publication number: 20150010473Abstract: The present invention is directed to methods and compositions for the treatment and diagnosis of neuroectodermally-derived tumors, such as gliomas. The inventive methods of treatment generally include local (e.g., intracavitary) administration of a chloroxotoxin moiety conjugated to a cytotoxic moiety to a patient. Also provided are diagnostic methods for screening neoplastic neuroectodermal tumors.Type: ApplicationFiled: July 11, 2014Publication date: January 8, 2015Inventor: Vernon Leon ALVAREZ
-
Publication number: 20150004099Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20150004253Abstract: The present invention relates to an in vitro method for the prognosis of the survival time of a patient suffering from a solid cancer, comprising the quantification of the cell density of follicular B cells present in tumor-induced lymphoid structures from said patient, wherein a high density of follicular B cells indicates that the patient has a favorable prognosis and a low density of follicular B cells indicates that the patient has a poor prognosis.Type: ApplicationFiled: January 21, 2013Publication date: January 1, 2015Inventors: Marie-Caroline Dieu-Nosjean, Wolf Herve Fridman, Romain Remark, Catherine Sautes-Fridman
-
Patent number: 8921058Abstract: Newly identified proteins as markers for the detection of prostate tumors, or as targets for their therapeutic treatment, affinity ligands capable of selectively interacting with said markers as well as methods for tumor diagnosis and therapy using the same.Type: GrantFiled: October 26, 2010Date of Patent: December 30, 2014Assignee: Externautics SpAInventors: Renata Grifantini, Piero Pileri, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Andrea Pierleoni, Renzo Nogarotto
-
Patent number: 8921070Abstract: The invention relates to the diagnosis of bladder cancer and more specifically to the detection in urine samples of bladder carcinomas of the transitional type. The detection method according to the present invention enables, through the utilization of a DNA chip designed for this purpose, to determine the grade of the detected tumors.Type: GrantFiled: May 13, 2011Date of Patent: December 30, 2014Assignee: Array GenomicsInventors: Olivier Cussenot, Ian Jones, Neil Metters, François Lozach
-
Patent number: 8921057Abstract: A CDK profile including a ratio of specific activities of two cyclin dependent kinases closely correlates with the malignancy grade and the presence/absence of the sensitivity to an irritant such as an anticancer agent of a cancer tissue in clinical medicine. Therefore, the properties of a mammalian cell, such as malignancy grade, proliferation potency, sensitivity to an irritant such as an anticancer agent can be assessed based on its CDK profile or by comparing the result of a specific activity ratio of two CDKs with a predetermined threshold corresponding to the ratio. This sensitivity assessing method shows a high ratio of correct assessing results particularly in positive or sensitivity and is useful in predicting efficacy of chemotherapy using the anticancer agent.Type: GrantFiled: May 30, 2005Date of Patent: December 30, 2014Assignee: Sysmex CorporationInventors: Hideki Ishihara, Tomoko Matsushima, Yuko Kawasaki
-
Publication number: 20140377286Abstract: The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.Type: ApplicationFiled: February 8, 2013Publication date: December 25, 2014Applicant: SEATTLE GENETICS, INC.Inventors: Tina Albertson, Maria L. Smith
-
Publication number: 20140378389Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.Type: ApplicationFiled: September 11, 2012Publication date: December 25, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
-
Publication number: 20140377779Abstract: A composition for breast cancer diagnosis using a material specifically binding to a polymeric immunoglobulin receptor (PIGR) or a fragment thereof, and a method for detecting breast cancer or acquiring information for breast cancer diagnosis using the composition.Type: ApplicationFiled: March 17, 2014Publication date: December 25, 2014Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: YE-RYOUNG YONG, GA-HEE KIM, HYUN-JU KANG
-
Publication number: 20140377781Abstract: Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.Type: ApplicationFiled: September 10, 2014Publication date: December 25, 2014Inventor: Kenji YOSHIDA
-
Publication number: 20140377782Abstract: An immunohistochemical staining of small specimen comprises using a plurality of antibodies and/or antigens to mark certain cells with particular colors of stains in order to distinguish target cells, such as carcinoma cells, in a stained small specimen. For example, antibodies CD44, cytokeratin 20 and p53 may be used for selectively staining a specimen of a urothelial mucosal biopsy on a single slide. Mouse monoclonal antibody CD44 is associated only with reactive urothelial cells, while rabbit monoclonal antibody p53 is associated only with carcinoma cells. Mouse monoclonal antibody cytokeratin 20 is associated with both “umbrella cells” and carcinoma cells, but antibody p53 is not associated with umbrella cells, which are the most superficial urothelial cells and are characterized morphologically from the other cells in a prepared specimen. Thus, diagnosis is facilitated by the staining of carcinoma cells in a contrasting color to normal urothelial cells and superficial urothelial cells.Type: ApplicationFiled: September 10, 2014Publication date: December 25, 2014Inventor: Peter Tsivis
-
Publication number: 20140377780Abstract: The present invention relates to a method for identifying neovascular structures in mammalian tissue, wherein said neovascular structures are identified by the detection of at least one specific protein in said tissue. It also relates to a method for identifying diseases or conditions associated with neovascularization, methods for targeting and/or imaging neovascular structures and methods for targeting diseases or conditions associated with neovascularization. Furthermore, the present invention is directed to the use of novel and/or known ligands, preferably antibodies, directed against novel and/or known target proteins for identifying tumor cells in mammalian tissue, preferably mammalian kidney tissue, more preferably mammalian vascular kidney tissue.Type: ApplicationFiled: September 2, 2014Publication date: December 25, 2014Inventors: Dario NERI, Christoph Rosli, Jascha RYBAK
-
Publication number: 20140378500Abstract: A method for identifying cancer patients that are likely to be responders or non-responders to a signal transduction pathway inhibitor is described.Type: ApplicationFiled: February 1, 2013Publication date: December 25, 2014Applicant: 20/20 GENE SYSTEMS, INC.Inventors: Jonathan Cohen, Alexandrine Josephe Derrien-Colemyn, John Gillespie, Soon Sik Park
-
Publication number: 20140378469Abstract: LKB1 mutation status and/or expression, YES expression and phosphorylation level; and/or CD24 expression are employed to predict melanoma prognosis and response to therapeutics. Inhibitors (including targeted inhibitors) of SRC family kinases (especially YES) are employed to treat melanoma.Type: ApplicationFiled: February 6, 2013Publication date: December 25, 2014Inventors: Norman Edward Sharpless, Wenjin Liu, James Bear, Kimberly Monahan, Kwok-Kin Wong
-
Publication number: 20140377182Abstract: Methods are provided for producing novel multicellular compositions comprising cancer cells together with pluripotent human stem cells, which are capable of proliferating and differentiating into various normal cell lines and tissue structures. These novel multicellular compositions are useful for investigating the properties of cancer cells in a normal human tissue microenvironment, and for studying interventions that will modulate these properties including devising, testing and screening therapeutic drugs.Type: ApplicationFiled: June 2, 2014Publication date: December 25, 2014Applicant: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.Inventors: Karl L. SKORECKI, Maty TZUKERMAN
-
Patent number: 8916342Abstract: A method and a kit for determining a disease stage of a papilloma virus infection in a human subject is disclosed. The method comprises: obtaining a sample from said human subject, said sample consisting of a tissue sample comprising proteins or a cell sample comprising proteins; contacting said sample with one or more antibodies that specifically bind to one or more recombinant HPV proteins; determining a presence, absence, or amount of at least one protein in said sample that specifically binds to said antibodies and determining said disease stage of papilloma virus infection in said human subject based on said determined presence, absence, or amount of said one or more proteins.Type: GrantFiled: May 6, 2010Date of Patent: December 23, 2014Assignee: OncoHealth Corp.Inventor: Shuling Cheng
-
Publication number: 20140370025Abstract: Provided are methods of treatment for tumors. In particular, provided are methods of using of a cytokine molecule and its receptor.Type: ApplicationFiled: August 29, 2014Publication date: December 18, 2014Inventor: Martin Oft
-
Publication number: 20140370023Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.Type: ApplicationFiled: May 27, 2014Publication date: December 18, 2014Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
-
Publication number: 20140371156Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.Type: ApplicationFiled: August 27, 2014Publication date: December 18, 2014Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORKInventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
-
Patent number: 8911950Abstract: Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.Type: GrantFiled: August 29, 2011Date of Patent: December 16, 2014Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Publication number: 20140363429Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.Type: ApplicationFiled: November 20, 2012Publication date: December 11, 2014Applicant: MedImmune LLCInventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
-
Publication number: 20140363826Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Applicant: STEM CENTRX, INC.Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
-
Publication number: 20140364402Abstract: The present invention provides, inter alia, a method for identifying an agent that selectively decreases the number of cancer stem cells (CSCs). This method includes (a) contacting a CSC from a population of cells with a candidate agent; and (b) determining whether the candidate agent reduces the survival or growth of the CSC or increases differentiation of the CSC relative to a CSC that has not been contacted with the candidate agent. The method may be used as a high throughput screen.Type: ApplicationFiled: March 22, 2012Publication date: December 11, 2014Applicant: THE ROGOSIN INSTITUTEInventors: Barry Smith, Carlos Cordon-Cardo, Daniel Petrylak, Josep Domenech, Mireia Castilla Martin
-
Publication number: 20140356365Abstract: Methods and agents are disclosed based on the finding that 5T4 interacts with CXCR4 in the cell membrane to form a complex, and that the 5T4 transmembrane region is involved in the promotion of CXCR4 membrane expression and chemotactic response.Type: ApplicationFiled: April 10, 2014Publication date: December 4, 2014Applicant: Cancer Research Technology LimitedInventors: Peter L. Stern, Vaskar Saha
-
Publication number: 20140357511Abstract: A system and method for isolating cells, comprising: a substrate having a broad surface; an array comprising a set of wells defined at the broad surface of the substrate, each well including: a base surface, an open surface directly opposing the base surface, defined at the broad surface of the substrate, and configured to receive one of a single cell and a single cluster of cells from a direction perpendicular to the broad surface of the substrate, and a set of channels that fluidly couple each well to at least one adjacent well; wherein the set of wells includes an interior subset and an exterior subset fluidly coupled to and surrounding the interior subset by way of the set of channels; and a fluid delivery module surrounding the array and fluidly coupled to each well in the set of wells.Type: ApplicationFiled: May 28, 2014Publication date: December 4, 2014Applicant: DeNovo SciencesInventors: Kalyan Handique, Priyadarshini Gogoi, Yi Zhou, Saedeh Sepehri, Christopher Siemer
-
Patent number: 8900881Abstract: The present invention relates to a quantitative assay device and a method for the determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains two bands having deposited on there high and low concentrations of different calibrator agents and a test band capable of reacting with conjugated analyte complexes giving rise to a measurable signal.Type: GrantFiled: September 12, 2011Date of Patent: December 2, 2014Inventor: Jin Po Lee
-
Publication number: 20140348819Abstract: The present invention provides methods of treating cancer.Type: ApplicationFiled: June 22, 2012Publication date: November 27, 2014Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.Inventors: Todd Golub, Ravid Straussman
-
Publication number: 20140348744Abstract: The use of luteinizing hormone receptor (LHR) as a treatment target in cancer is provided. Data demonstrates that LHR plays an important role in androgen synthesis and signaling pathways critical for prostate cancer progression. When LHR is silenced, there is a significant downregulation of androgen receptor (AR) mRNA and protein expression with a subsequent suppression of PSA expression. Data suggesting that the LH-LHR signaling cascade may be an upstream and viable therapeutic target in castration-resistant prostate cancer (CRPC) is presented.Type: ApplicationFiled: May 27, 2014Publication date: November 27, 2014Inventor: Jacek K. Pinski
-
Patent number: 8895697Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.Type: GrantFiled: September 9, 2010Date of Patent: November 25, 2014Assignee: Natimab Therapeutics S.r.l.Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
-
Publication number: 20140341922Abstract: Provided are a pharmaceutical composition for suppressing a resistance to a targeted anticancer drug, which at least one selected from the group consisting of an integrin ?3 neutralizing antibody, integrin ?3 siRNA, Src inhibitor, and Src siRNA as an active ingredient, and an anticancer supplement. The pharmaceutical composition may increase an anticancer therapeutic effect when administered in combination with a conventional targeted anticancer drug. In addition, the pharmaceutical composition is expected to be used in development of an integrin ?3-targeted targeted anticancer drug.Type: ApplicationFiled: November 23, 2012Publication date: November 20, 2014Inventor: Ho Young Lee
-
Publication number: 20140342920Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods of classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the same for a mutation in one or more biomarkers.Type: ApplicationFiled: May 20, 2014Publication date: November 20, 2014Applicant: British Columbia Cancer Agency BranchInventors: Ryan D. Morin, Marco A. Marra, Andrew J. Mungall, Martin Hirst, Maria Mendez-Lago, Randy D. Gascoyne, Joseph M. Connors
-
Publication number: 20140342374Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.Type: ApplicationFiled: May 2, 2014Publication date: November 20, 2014Applicant: Dinona Inc.Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
-
Publication number: 20140343051Abstract: Novel methods for modulating acute myeloid leukemia stem/progenitor cell expansion and/or differentiation are disclosed. These methods are based on the use of aryl hydrocarbon receptor (AhR) modulators and/or compounds of formula I or II Screening assays to identify compounds that may be useful for inhibiting and/or eliminating AML initiating cells using AhR modulators and/or the compounds of formula I or II are also disclosed. The use of pharmaceutically acceptable agonists of the AhR for preventing or inhibiting minimal residual disease (MRD) in an AML patient is also disclosed.Type: ApplicationFiled: April 4, 2014Publication date: November 20, 2014Inventors: GUY SAUVAGEAU, JOSEE HEBERT, CAROLINE PABST
-
Publication number: 20140341897Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventor: Daniel John O'Shannessy